Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Viridian Therapeutics, Inc.\de (VRDN) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Viridian Therapeutics, Inc.\de. Table 2 shows the detailed insider transactions. This company's CIK number is 1590750.
Total stock buying since 2015: $58,462,828.
Total stock sales since 2015: $9,978,095.
Total stock option exercises since 2015: $4,673,601.
Insider Buying | Insider Sales | Option Exercises | ||||
---|---|---|---|---|---|---|
Year | Shares | Value | Shares | Value | Shares | Value |
2025 | 0 | $0 | 0 | $0 | 14,100 | $166,355 |
2024 | 2,102,590 | $40,616,301 | 0 | $0 | 0 | $0 |
2023 | 9,500 | $261,805 | 185,610 | $6,373,483 | 105,639 | $2,359,610 |
2022 | 0 | $0 | 175,978 | $3,108,686 | 25,978 | $524,903 |
2021 | 1,109,000 | $12,199,000 | 0 | $0 | 0 | $0 |
2020 | 476,667 | $2,275,461 | 0 | $0 | 11,249 | $6,411 |
2019 | 0 | $0 | 0 | $0 | 3,093 | $1,763 |
2018 | 564,544 | $3,097,691 | 0 | $0 | 145,348 | $82,848 |
2017 | 200 | $1,510 | 38,702 | $495,926 | 282,667 | $1,531,711 |
2016 | 0 | $0 | 0 | $0 | 617,503 | $0 |
2015 | 14,000 | $11,060 | 0 | $0 | 536,508 | $0 |
Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
---|---|---|---|---|---|---|
year-month | Shares | Value | Shares | Value | Shares | Value |
2025-06 | 0 | $0 | 0 | $0 | 14,100 | $166,355 |
2024-09 | 1,626,400 | $30,616,311 | 0 | $0 | 0 | $0 |
2024-01 | 476,190 | $9,999,990 | 0 | $0 | 0 | $0 |
2023-06 | 0 | $0 | 9,796 | $250,476 | 9,796 | $183,244 |
2023-04 | 4,000 | $101,480 | 0 | $0 | 0 | $0 |
2023-03 | 5,500 | $160,325 | 29,971 | $871,256 | 0 | $0 |
2023-02 | 0 | $0 | 50,000 | $1,839,999 | 0 | $0 |
2023-01 | 0 | $0 | 95,843 | $3,411,752 | 95,843 | $2,176,366 |
2022-12 | 0 | $0 | 17,853 | $502,386 | 17,853 | $411,153 |
2022-11 | 0 | $0 | 8,125 | $179,156 | 8,125 | $113,750 |
2022-06 | 0 | $0 | 30,000 | $366,000 | 0 | $0 |
2022-05 | 0 | $0 | 30,000 | $391,200 | 0 | $0 |
2022-04 | 0 | $0 | 30,000 | $567,636 | 0 | $0 |
2022-03 | 0 | $0 | 30,000 | $529,491 | 0 | $0 |
2022-02 | 0 | $0 | 30,000 | $572,817 | 0 | $0 |
2021-09 | 1,109,000 | $12,199,000 | 0 | $0 | 0 | $0 |
2020-11 | 476,667 | $2,275,461 | 0 | $0 | 0 | $0 |
2020-03 | 0 | $0 | 0 | $0 | 11,249 | $6,411 |
2019-08 | 0 | $0 | 0 | $0 | 3,093 | $1,763 |
2018-10 | 10,000 | $47,699 | 0 | $0 | 0 | $0 |
2018-08 | 0 | $0 | 0 | $0 | 29,530 | $16,832 |
2018-02 | 554,544 | $3,049,992 | 0 | $0 | 115,818 | $66,016 |
2017-12 | 0 | $0 | 12,000 | $96,000 | 0 | $0 |
2017-06 | 200 | $1,510 | 0 | $0 | 0 | $0 |
Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-06-10 | Fairmount Healthcare Fund Ii L.p. | Option Ex | 12,500 | 12.31 | 153,875 |
2025-06-09 | Fairmount Healthcare Fund Ii L.p. | Option Ex | 1,600 | 7.80 | 12,480 |
2024-09-27 | Mahoney Stephen F. (President and CEO) | Buy | 21,400 | 23.33 | 499,261 |
2024-09-27 | Beetham Thomas W. (Chief Operating Officer) | Buy | 5,000 | 23.41 | 117,050 |
2024-09-13 | Fairmount Healthcare Fund Ii L.p. | Buy | 1,600,000 | 18.75 | 30,000,000 |
2024-01-22 | Fairmount Healthcare Fund Ii L.p. | Buy | 476,190 | 21.00 | 9,999,990 |
2023-06-16 | Meisner Lara (Chief Legal Officer) | Sale | 27 | 28.35 | 765 |
2023-06-16 | Meisner Lara (Chief Legal Officer) | Option Ex | 27 | 23.03 | 621 |
2023-06-15 | Meisner Lara (Chief Legal Officer) | Sale | 2,269 | 28.02 | 63,577 |
2023-06-15 | Meisner Lara (Chief Legal Officer) | Option Ex | 2,269 | 23.03 | 52,255 |
2023-06-06 | Meisner Lara (Chief Legal Officer) | Sale | 5,126 | 25.02 | 128,252 |
2023-06-06 | Meisner Lara (Chief Legal Officer) | Option Ex | 5,126 | 18.51 | 94,882 |
2023-06-05 | Meisner Lara (Chief Legal Officer) | Sale | 499 | 25.03 | 12,489 |
2023-06-05 | Meisner Lara (Chief Legal Officer) | Option Ex | 499 | 18.51 | 9,236 |
2023-06-02 | Meisner Lara (Chief Legal Officer) | Sale | 1,875 | 24.21 | 45,393 |
2023-06-02 | Meisner Lara (Chief Legal Officer) | Option Ex | 1,875 | 14.00 | 26,250 |
2023-04-12 | Myers Scott Dunseth (Chief Executive Officer) | Buy | 4,000 | 25.37 | 101,480 |
2023-03-13 | Myers Scott Dunseth (Chief Executive Officer) | Buy | 5,500 | 29.15 | 160,325 |
2023-03-09 | Meisner Lara (General Counsel and Secretary) | Sale | 29,971 | 29.07 | 871,256 |
2023-02-02 | Violin Jonathan (Chief Executive Officer) | Sale | 50,000 | 36.80 | 1,839,999 |
2023-01-23 | Meisner Lara (General Counsel and Secretary) | Sale | 6,843 | 35.66 | 244,021 |
2023-01-23 | Meisner Lara (General Counsel and Secretary) | Option Ex | 6,843 | 18.52 | 126,698 |
2023-01-17 | Katz Barrett (Chief Medical Officer) | Sale | 24,853 | 37.21 | 924,780 |
2023-01-17 | Katz Barrett (Chief Medical Officer) | Option Ex | 24,853 | 23.03 | 572,364 |
2023-01-13 | Katz Barrett (Chief Medical Officer) | Sale | 4,147 | 37.01 | 153,480 |
2023-01-13 | Katz Barrett (Chief Medical Officer) | Option Ex | 4,147 | 23.03 | 95,505 |
2023-01-10 | Katz Barrett (Chief Medical Officer) | Sale | 47,377 | 35.30 | 1,672,408 |
2023-01-10 | Katz Barrett (Chief Medical Officer) | Option Ex | 47,377 | 23.03 | 1,091,092 |
2023-01-09 | Katz Barrett (Chief Medical Officer) | Sale | 12,623 | 33.04 | 417,063 |
2023-01-09 | Katz Barrett (Chief Medical Officer) | Option Ex | 12,623 | 23.03 | 290,707 |
2022-12-16 | Meisner Lara (General Counsel and Secretary) | Sale | 1,297 | 28.44 | 36,886 |
2022-12-16 | Meisner Lara (General Counsel and Secretary) | Option Ex | 1,297 | 23.03 | 29,869 |
2022-12-15 | Meisner Lara (General Counsel and Secretary) | Sale | 300 | 28.08 | 8,424 |
2022-12-15 | Meisner Lara (General Counsel and Secretary) | Option Ex | 300 | 23.03 | 6,909 |
2022-12-14 | Meisner Lara (General Counsel and Secretary) | Sale | 15,656 | 28.12 | 440,246 |
2022-12-14 | Meisner Lara (General Counsel and Secretary) | Option Ex | 15,656 | 23.03 | 360,557 |
2022-12-12 | Meisner Lara (General Counsel and Secretary) | Sale | 600 | 28.05 | 16,830 |
2022-12-12 | Meisner Lara (General Counsel and Secretary) | Option Ex | 600 | 23.03 | 13,818 |
2022-11-15 | Meisner Lara (General Counsel and Secretary) | Sale | 8,125 | 22.05 | 179,156 |
2022-11-15 | Meisner Lara (General Counsel and Secretary) | Option Ex | 8,125 | 14.00 | 113,750 |
2022-06-01 | Violin Jonathan (Chief Executive Officer) | Sale | 30,000 | 12.20 | 366,000 |
2022-05-02 | Violin Jonathan (Chief Executive Officer) | Sale | 30,000 | 13.04 | 391,200 |
2022-04-04 | Violin Jonathan (Chief Executive Officer) | Sale | 3,600 | 18.93 | 68,148 |
2022-04-01 | Violin Jonathan (Chief Executive Officer) | Sale | 26,400 | 18.92 | 499,488 |
2022-03-02 | Violin Jonathan (Chief Executive Officer) | Sale | 11,106 | 17.36 | 192,800 |
2022-03-01 | Violin Jonathan (Chief Executive Officer) | Sale | 18,894 | 17.82 | 336,691 |
2022-02-03 | Violin Jonathan (Chief Executive Officer) | Sale | 909 | 19.16 | 17,416 |
2022-02-02 | Violin Jonathan (Chief Executive Officer) | Sale | 12,340 | 18.47 | 227,919 |
2022-02-01 | Violin Jonathan (Chief Executive Officer) | Sale | 16,751 | 19.55 | 327,482 |
2021-09-23 | Fhmlsp, L.l.c. (10% Owner) | Buy | 200,000 | 11.00 | 2,200,000 |
2021-09-21 | Fairmount Healthcare Fund Ii L.p. (Director) | Buy | 909,000 | 11.00 | 9,999,000 |
2020-11-13 | Logos Global Master Fund Lp | Buy | 126,667 | 14.84 | 1,879,611 |
2020-11-09 | Logos Global Master Fund Lp | Buy | 350,000 | 1.13 | 395,850 |
2020-03-13 | Leverone Jason A. (CFO, Treasurer & Secretary) | Option Ex | 11,249 | .57 | 6,411 |
2019-08-23 | Leverone Jason A. (CFO, Treasurer & Secretary) | Option Ex | 3,093 | .57 | 1,763 |
2018-10-11 | Hughes Thomas E. (Director) | Buy | 10,000 | 4.77 | 47,699 |
2018-08-07 | Leverone Jason A. (CFO, Treasurer & Secretary) | Option Ex | 29,530 | .57 | 16,832 |
2018-02-13 | Levy Adam Scott (Chief Business Officer) | Buy | 9,090 | 5.50 | 49,995 |
2018-02-13 | Marshall William Stuart (President & CEO) | Option Ex | 115,818 | .57 | 66,016 |
2018-02-13 | Booth Bruce (Director) | Buy | 545,454 | 5.50 | 2,999,997 |
2017-12-20 | Hughes Thomas E. (Director) | Sale | 12,000 | 8.00 | 96,000 |
2017-06-22 | Levy Adam Scott (Chief Business Officer) | Buy | 200 | 7.55 | 1,510 |
2017-03-10 | Lefkoff Kyle (Director) | Sale | 3,300 | 14.31 | 47,229 |
2017-03-09 | Lefkoff Kyle (Director) | Sale | 2,500 | 14.38 | 35,962 |
2017-03-08 | Lefkoff Kyle (Director) | Sale | 5,000 | 14.70 | 73,515 |
2017-03-06 | Lefkoff Kyle (Director) | Sale | 10,000 | 15.98 | 159,770 |
2017-02-23 | Lefkoff Kyle (Director) | Sale | 1,800 | 13.65 | 24,566 |
2017-02-22 | Lefkoff Kyle (Director) | Sale | 4,102 | 14.36 | 58,884 |
2017-02-13 | Lebow Bennett S (Director) | Option Ex | 279,067 | 5.39 | 1,504,171 |
2017-02-08 | Gonyer David A (Director) | Option Ex | 1,200 | 7.65 | 9,180 |
2017-02-03 | Smith Robin L (Director) | Option Ex | 1,200 | 7.65 | 9,180 |
2017-02-03 | Lebow Bennett S (Director) | Option Ex | 1,200 | 7.65 | 9,180 |
2016-10-31 | Riccitelli Samuel D (President & CEO) | Option Ex | 200,000 | .00 | 0 |
2016-10-31 | Seymour Tamara A (CFO, Secretary, Treasurer) | Option Ex | 146,000 | .00 | 0 |
2016-08-08 | Seymour Tamara A (CFO, Secretary, Treasurer) | Option Ex | 23,000 | .00 | 0 |
2016-06-28 | Riccitelli Samuel D (President & CEO) | Option Ex | 124,251 | .00 | 0 |
2016-02-11 | Riccitelli Samuel D (President & CEO) | Option Ex | 124,252 | .00 | 0 |
2015-11-20 | Riccitelli Samuel D (President & CEO) | Buy | 7,000 | .80 | 5,600 |
2015-11-19 | Riccitelli Samuel D (President & CEO) | Buy | 7,000 | .78 | 5,460 |
2015-08-06 | Gonyer David A (Director) | Option Ex | 4,125 | .00 | 0 |
2015-08-06 | Schuling Douglas A (Director) | Option Ex | 4,125 | .00 | 0 |
2015-08-06 | Smith Robin L (Director) | Option Ex | 4,125 | .00 | 0 |
2015-08-04 | Seymour Tamara A (CFO, Secretary, Treasurer) | Option Ex | 23,000 | .00 | 0 |
2015-07-17 | Gonyer David A (Director) | Option Ex | 1,375 | .00 | 0 |
2015-07-17 | Schuling Douglas A (Director) | Option Ex | 1,375 | .00 | 0 |
2015-07-17 | Smith Robin L (Director) | Option Ex | 1,375 | .00 | 0 |
2015-06-19 | Riccitelli Samuel D (President and CEO) | Option Ex | 124,252 | .00 | 0 |
2015-04-08 | Riccitelli Samuel D (President and CEO) | Option Ex | 372,756 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of VRDN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Viridian Therapeutics, Inc.\de (symbol VRDN, CIK number 1590750) see the Securities and Exchange Commission (SEC) website.